INVESTOR RELATIONS COMPANY PLATFORMS CLINICAL STUDIES CAREERS PUBLICATIONS NEWS CONTACT Explore publications and presentations that bring our science to life. ALL PRESENTATIONS CLINICAL DATA PRECLINICAL DATA REFERENCES Download our Latest Non-confidential Investor Presentation Download our mRNA Engineered Cell & Cytokine Medicines Presentation IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death Czystowska M, Han J, Szczepanski MJ, et al. Cell Death Differ. 2009;16(5):708-718. Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic Czystowska M, Szczepanski MJ, Szajnik M, et al. Cancer Immunol Immunother. 2011;60(4):495-506. IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro Egan JE, Quadrini KJ, Santiago-Schwarz F, Hadden JW, Brandwein HJ, Signorelli KL. J Immunother. 2007;30(6):624-633. IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells Schilling B, Harasymczuk M, Schuler P, Egan J, Ferrone S, Whiteside TL. PLoS One. 2013;8(2):e47234. IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model Schilling B, Harasymczuk M, Schuler P, Egan JE, Whiteside TL. J Mol Med (Berl). 2012;90(2):139-147. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients. Schilling B, Halstead ES, Schuler P, Harasymczuk M, Egan JE, Whiteside TL. Cancer Immunol Immunother. 2012;61(9):1395-1405. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines. Naylor PH, Hernandez KE, Nixon AE, et al. Vaccine. 2010;28(43):7054-7062 Peptide based vaccine approaches for cancer—a novel approach using a WT-1 synthetic long peptide and the IRX-2 immunomodulatory regimen. Naylor PH, Egan JE, Berinstein NL. Cancers (Basel). 2011;3(4):3991-4009. 1 2 Privacy Policy Terms of Use © 2021 Brooklyn ImmunoTherapeutics